J&J lawsuit against Amgen (Nov 2022) over Amgens biosimilar of Stelara has been settled (terms undisclosed) such that the Amgen biosimilar cannot be US marketed until 1/1/2025. Stelaras 2022 revenue was $9.7 billion https://t.co/NVgBsBNxk1 https://t.co/Fj8rn05RW0